Table 2.
Univariate analysis of the impact of various clinicopathologic factors on the risk of biochemical recurrence after salvage ADT
| No. of patients | p-value | |
|---|---|---|
| Treatment group | 0.0279* | |
| Ultra-early salvage ADT | 51 | |
| Early salvage ADT | 70 | |
| Age, years | 0.0798 | |
| <70 | 82 | |
| ≥70 | 39 | |
| Preoperative PSA, ng/ml | 0.0493* | |
| <20 | 107 | |
| ≥20 | 14 | |
| Pathologic Gleason score | 0.0043* | |
| ≤7 | 101 | |
| ≥8 | 20 | |
| Pathologic tumor stage | 0.5690 | |
| ≤2 | 77 | |
| ≥3 | 44 | |
| Extraprostatic extension | 0.7106 | |
| 0 | 79 | |
| 1 | 42 | |
| Lymphovascular invasion | 0.4606 | |
| 0 | 92 | |
| 1 | 29 | |
| Positive resection margin | 0.4467 | |
| 0 | 41 | |
| 1 | 80 | |
| Seminal vesicle invasion | 0.3978 | |
| 0 | 117 | |
| 1 | 4 | |
| Perineural invasion | 0.5035 | |
| 0 | 43 | |
| 1 | 78 |
ADT, androgen deprivation therapy; *statistically significant; PSA, prostate-specific antigen.